Ask the expert
The report presents a summary of reimbursement situation for cardiac pacemakers.
Both single- and dual-chamber pacemakers are considered. Use of pacemakers is considered in complete atrioventricular block and obstructive hypertrophic cardiomyopathy.
Reimbursement analysis covers the following procedures: implantation, replacement and removal of pacemaker.
The only reimbursement within public / statutory health insurance systems is considered.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of devices for cardiac pacemakers include:
- Abbott Vascular (Assurity MRI, Endurity MRI)
- Biotronik (Enitra, Effecta, Epyra, Estella, Evia, Edora)
- Boston Scientific (Essentio, Accolade, Ingenio, Advantio, Vitalio)
- Qinming Medical (Qinming)
- MicroPort CRM (Kora, Reply, Esprit)
- Medico S.p.A. (Gea, Hera, Eos, Sophos, Helios, Mythos, Easy Plus)
- Medtronic (Azure, Advisa MRI, Adapta, Micra, Revo MRI SureScan, Sensia, Versa, EnRhythm, EnPulse, Sigma, Kappa)
- Pacetronix (Tiranga, Pinnacle, CHARAK, Pinnacle-R)
- Vitatron (Vitatron)
Table of content is not available at the moment. Report is still ongoing.
The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2021. Recommendations concern cardiovascular and peripheral vascular devices, orthopedic devices, liquid for embolization, and medical aids.Read more
In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.Read more
In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.Read more
In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.Read more
The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.Read more